Skip to main content
Figure 1 | BMC Complementary and Alternative Medicine

Figure 1

From: Anti-osteoclastogenic activity of matairesinol via suppression of p38/ERK-NFATc1 signaling axis

Figure 1

Matairesinol inhibits RANKL-mediated osteoclast differentiation. (A) Structure of matairesinol. (B) BMMs were cultured for 4 days in the presence of RANKL (10 ng/ml) and M-CSF (30 ng/ml) with the vehicle (DMSO) or matairesinol. Multinucleated osteoclasts were visualized by TRAP staining. (C) TRAP-positive multinuclear cells (MNCs) were counted. **, P < 0.01; ***, P < 0.001 (versus the control). (D) TRAP activity was measured. ###, P < 0.001 (versus the negative control); *, P < 0.05; **, P < 0.01; ***, P < 0.001 (versus the RANKL-treated control). (E) Effect of matairesinol on the viability of BMMs was evaluated using the CCK-8 assay.

Back to article page